EDEN PRAIRIE, Minn., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) today announced that Chief Executive Officer, Dave Rosa, will be featured on Bloomberg Television's Taking Stock on Wednesday, February 5, 2014 at 5:00 pm EST. Hosted by Bloomberg anchor Pimm Fox, Taking Stock is a daily investment-focused program featuring conversations with leading Wall Street analysts, fund managers and CEOs, offering insight into company news, market and trading strategies across equities, fixed income, commodities, and currencies. Following the segment, a link to a recording of the program will be posted to the investor page of Sunshine Heart's website at: http://ir.sunshineheart.com.
The segment will focus on Sunshine Heart's C-Pulse Heart Assist System, an investigational device designed to treat clinical symptoms associated with Class III and ambulatory Class IV heart failure. The device is currently used in an ongoing U.S. randomized controlled clinical trial, COUNTER HF™; as well as in a post-market study throughout Europe, OPTIONS HF. Sunshine Heart received CE Mark certification for its C-Pulse device in the EU in July of 2012. The device can be implanted via a minimally invasive procedure or a full sternotomy. Operating outside the patient's bloodstream, the extra-aortic approach of C-Pulse offers significant potential safety advantages to existing therapies, as well as greater flexibility, allowing patients to have intervals of freedom to disconnect from the device. A fully implantable device is currently under development, with a chronic animal trial successfully completed with the device showing a comparable level of support to the first generation C-Pulse system.
As previously announced, Sunshine Heart plans to release its fourth quarter and full year 2013 audited results in early March of 2014.
About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility trial, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their condition as a result of the therapy.
Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.
About Sunshine® Heart
Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical trial of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal trial. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia. The Company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, future clinical trial activities and results including patient enrollment in trials. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical trials do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption "Risk Factors" and elsewhere in our filings with the SEC. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.